Abbott Laboratories

Equities

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 01:30:13 17/07/2024 am IST			5-day change	1st Jan Change
102.7 ^USD	-0.23%		+1.06%	-6.68%

15/07	Equity Markets Higher After Fed Chair Powell's Comments	MT
15/07	Equity Markets Rise Intraday After Fed Chair Powell's Comments	MT

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

January 24, 2024 at 06:00 pm IST

Abbott Laboratories provided earnings guidance for the full year 2024. For the period, the company issued full-year 2024 diluted earnings per share guidance under GAAP of $3.20 to $3.40. The company continues to project full-year 2024 organic sales growth, excluding COVID-19 testing-related sales, to be in the range of 8% to 10%.

Latest news about Abbott Laboratories

Equity Markets Higher After Fed Chair Powell's Comments	16/07	MT
Equity Markets Rise Intraday After Fed Chair Powell's Comments	16/07	MT
Medical Technology Companies Poised for Another 'Solid' Quarter, Morgan Stanley Says	15/07	MT
Stocks Gain Pre-Bell Ahead of Key Earnings; Asia Mixed, Europe Down	15/07	MT
S&P 500 Rises Week-to-Week, Closes Near Highs Despite Mixed Inflation Data, Bank Earnings	13/07	MT
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $118 From $121	10/07	MT
DexCom, Inc. : A Must-Have Tool for Diabetes Care	10/07
That's not so bad, is it?	08/07
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $125, Maintains Outperform Rating	02/07	MT
Abbott Laboratories(NYSE:ABT) dropped from Russell Top 200 Growth Index	01/07	CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 3000 Growth Index	01/07	CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 3000E Growth Index	01/07	CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth Index	01/07	CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index	01/07	CI
Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health	20/06	CI
Abbott Laboratories Keeps Quarterly Dividend at $0.55 Per Share, Payable on Aug.15 to Shareholders of Record on July 15	14/06	MT
Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024	14/06	CI
Abbott Laboratories Says US FDA Approved 2 Over-The-Counter Continuous Glucose Monitoring Wearable Systems	10/06	MT
US FDA clears Abbott's continuous glucose monitors for over-the-counter use	10/06	RE
Abbott Receives U.S. FDA Clearance for Two New Over-The-Counter Continuous Glucose Monitoring Systems	10/06	CI
U.S. FDA set to reorganize its food division starting October	30/05	RE
Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115	30/05	MT
Medtronic beats quarterly profit estimates on medical devices strength	23/05	RE
Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating	22/05	MT
Abbott Laboratories Recalling HeartMate 3 Left Ventricular Assist System Implant Kit	15/05	MT

Chart Abbott Laboratories

Duration

Period

More charts

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

18/07/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Abbott Laboratories

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

103 USD

Average target price

124.8 USD

Spread / Average Target

+21.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-6.68%	18TCr
MEDTRONIC PLC	-5.20%	9.88TCr
BECTON, DICKINSON AND COMPANY	-5.38%	6.53TCr
HOYA CORPORATION	+15.46%	4.54TCr
DEXCOM, INC.	-6.47%	4.49TCr
CENCORA, INC.	+9.74%	4.38TCr
METTLER-TOLEDO INTERNATIONAL, INC.	+14.01%	2.9TCr
TERUMO CORPORATION	+19.39%	2.56TCr
WEST PHARMACEUTICAL SERVICES, INC.	-6.53%	2.33TCr
ZIMMER BIOMET HOLDINGS, INC.	-11.70%	2.19TCr

Other Medical Equipment, Supplies & Distribution